Clinical Trial Search

Primary: Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected Age (CA) — 0; 0; 12; 19 Participants

Primary: Number of Unanticipated Grade III or Higher Treatment-Related Toxicities — 0; 0 events

Primary: Percentage of Participants Who Were Alive and Have None of the 6 Major Functional Disabilities (MFDs) at Month 24 and Without Allo-HSCT or Rescue Cell Administration…

Primary: Number of Participants With a Decrease in Titer of One or More DSA (Either Reduced MFI or Absence of DSA on Same Dilution) — 17 Participants

Primary: Objective Response Rate — 44.4 percentage of participants

Primary: Number and Percentage of Patients Achieving Virologic Resuppression — 256; 263 Participants

Primary: Proportion of Patients Receiving Complete Induction Course — 0.833 proportion of patients

Primary: Proportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase — 50; 37 Participants

Primary: Efficacy Outcome - Number of Participants That Had Successful Termination of Ventricular Fibrillation Episodes at Implantation — 18 Participants

Primary: Number of Participants With Significant Increases in Socket Comfort Score (SCS) — 5; 6; 4 participants

Primary: Number of Participants Determined by a Dermatologist to Have a Clinically Relevant Positive Outcome for Cutaneous Irritation After 21 Days of Product Use — 1; 0; 0…

Primary: Change From Baseline of Lower Extremity Independence Time During 10 Min Standing Bout After 160 Sessions (1 Year) — 40.6 minutes

Primary: Number of Participants With Time to Progression (TTP) — 42; 4 Participants

Primary: Efficacy of Treatment at Day 28 as Assessed by Number of Participants Who Develop SARS-Cov-2 Infection — 12; 13 Participants — p=0.42

Primary: Visual Analog Scale (VAS) Pain Score — 64; 61 score on a scale